BDNF - a key transducer of antidepressant effects.
Carl Björkholm,Lisa M. Monteggia +1 more
Reads0
Chats0
TLDR
Current data suggests that conventional antidepressants and ketamine mediate their antidepressant-like effects by increasing BDNF in forebrain regions, in particular the hippocampus, making BDNF an essential determinant of antidepressant efficacy.About:
This article is published in Neuropharmacology.The article was published on 2016-03-01 and is currently open access. It has received 630 citations till now. The article focuses on the topics: Tropomyosin receptor kinase B & Brain-derived neurotrophic factor.read more
Citations
More filters
Journal ArticleDOI
Mechanisms of ketamine action as an antidepressant.
Panos Zanos,Todd D. Gould +1 more
TL;DR: In this article, the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5methyl-4-isoxazole-propionic acid receptor activation.
Journal ArticleDOI
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Bruno Lima Giacobbo,Janine Doorduin,Hans C. Klein,Rudi Dierckx,Elke Bromberg,Erik F. J. de Vries +5 more
TL;DR: The effect of acute and chronic inflammation on BDNF levels in the most common psychiatric and neurodegenerative disorders is focused on and some light is shed on the possible biological mechanisms that may influence this effect.
Journal ArticleDOI
How do antidepressants work? New perspectives for refining future treatment approaches
TL;DR: The ways in which monoamine neurotransmitter-based and neural plasticity theories reflect different or complementary approaches to antidepressant drug action are discussed, and how they might be integrated to offer novel solutions for people with depression are discussed.
Journal ArticleDOI
Dendritic Structural Plasticity and Neuropsychiatric Disease
TL;DR: The importance of recent genetic findings on the different mechanisms of structural plasticity are discussed and it is proposed that these converge on shared pathways that can be targeted with novel therapeutics.
Journal ArticleDOI
Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer.
TL;DR: The role of BDNF is illustrated as a potent protective factor that is able to confer protection against neurodegeneration, in particular in Alzheimer’s disease and how the involvement ofBDNF in the pathogenesis of brain glioblastoma has emerged is given, thus opening new avenues for the treatment of this deadly cancer.
References
More filters
Journal ArticleDOI
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
Michael F. Egan,Masami Kojima,Masami Kojima,Joseph H. Callicott,Terry E. Goldberg,Bhaskar Kolachana,Alessandro Bertolino,Eugene Zaitsev,Bert Gold,David Goldman,Michael Dean,Bai Lu,Daniel R. Weinberger +12 more
TL;DR: A role is demonstrated for BDNF and its val/met polymorphism in human memory and hippocampal function and it is suggested val/ met exerts these effects by impacting intracellular trafficking and activity-dependent secretion of BDNF.
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A neurotrophic model for stress-related mood disorders.
TL;DR: Analysis of preclinical cellular and behavioral models of depression and antidepressant actions, as well as clinical neuroimaging and postmortem studies, are consistent with the hypothesis that decreased expression of BDNF and possibly other growth factors contributes to depression and that upregulation ofBDNF plays a role in the actions of antidepressant treatment.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.